December 8, 2025BloodOpen Access

Genomic characterization uncovers molecular subtypes in Mantle Cell Lymphoma

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Analysis demonstrates survival improvements with BTK inhibitors in high-risk MCL subtypes, suggesting new treatment avenues.

Survival outcomes improved in high-risk mantle cell lymphoma patients with BTK inhibitors, particularly subtype C3.
Analysis of 104 MCL patients revealed three distinct molecular subtypes, each with varying prognoses.
Next-generation sequencing facilitated comprehensive genomic characterization and mutational profiling of MCL.
Targeting specific high-risk mutations like TP53 may enhance therapeutic strategies for MCL patients.

Yang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark